Publications
409 results found
Thursz M, Sadiq F, Tree JA, et al., 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2 (vol 104, 001865, 2023), JOURNAL OF GENERAL VIROLOGY, Vol: 104, ISSN: 0022-1317
Thursz M, Sadiq F, Tree JA, et al., 2023, Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS- CoV-2, JOURNAL OF GENERAL VIROLOGY, Vol: 104, ISSN: 0022-1317
- Author Web Link
- Cite
- Citations: 1
Wadsworth CA, Dixon PH, Taylor-Robinso SD, et al., 2019, Polymorphisms in natural killer cell receptor protein 2D (NKG2D) as a risk factor for Cholangiocarcinoma, Journal of Clinical and Experimental Hepatology, Vol: 9, Pages: 171-175, ISSN: 0973-6883
Background and aims: Understanding of the significant genetic risk factors for Cholangiocarcinoma (CC) remains limited. Polymorphisms in the natural killer cell receptor G2D (NKG2D) gene have been shown to increase risk of CC transformation in patients with Primary Sclerosing Cholangitis (PSC). We present a validation study of NKG2D polymorphisms in CC patients without PSC. Methods: Seven common Single Nucleotide Polymorphisms (SNPs) of the NKG2D gene were genotyped in 164 non-PSC related CC subjects and 257 controls with HaploView. The two SNPs that were positively identified in the previous Scandinavian study, rs11053781 and rs2617167, were included. Results: The seven genotyped SNPs were not associated with risk of CC. Furthermore, haplotype analysis revealed that there was no evidence to suggest that any haplotype differs in frequency between cases and controls (P > 0.1). Conclusion: The common genetic variation in NKG2D does not correlate significantly with sporadic CC risk. This is in contrast to the previous positive findings in the Scandinavian study with PSC-patients. The failure to reproduce the association may reflect an important difference between the pathogenesis of sporadic CC and that of PSC-related CC. Given that genetic susceptibility is likely to be multifaceted and complex, further validation studies that include both sporadic and PSC-related CC are required.
Papatheodoridis G, Thomas HC, Golna C, et al., 2016, Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference, JOURNAL OF VIRAL HEPATITIS, Vol: 23, Pages: 1-12, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 24
Walsh R, Hammond R, Yuen L, et al., 2015, Mapping HBsAg epitope profiles to predict HBsAg loss/seroconversion in a treatment naive cohort of genotype A chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) therapy, 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Publisher: WILEY-BLACKWELL, Pages: 966A-967A, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 2
Bermingham SL, Hughes R, Fenu E, et al., 2015, Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom, VALUE IN HEALTH, Vol: 18, Pages: 800-809, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 11
Bridge SH, Sheridan DA, Felmlee DJ, et al., 2015, PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism, JOURNAL OF HEPATOLOGY, Vol: 62, Pages: 763-770, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 31
Lim LY, Yuen L, Hammond R, et al., 2014, Mapping the HBsAg immune phenotype to predict HBsAg decline in chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol: 29, Pages: 154-154, ISSN: 0815-9319
Sheridan DA, Bridge SH, Crossey MME, et al., 2014, Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency, METABOLIC BRAIN DISEASE, Vol: 29, Pages: 625-634, ISSN: 0885-7490
- Author Web Link
- Cite
- Citations: 6
Sheridan DA, Bridge SH, Crossey MME, et al., 2014, Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial, LIVER INTERNATIONAL, Vol: 34, Pages: 737-747, ISSN: 1478-3223
- Author Web Link
- Cite
- Citations: 10
Lim LY, Yuen L, Hammond R, et al., 2014, Mapping the HBsAg immune phenotype to predict HBsAg loss or decline in chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy, 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 980A-980A, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 2
Forton DM, Taylor-Robinson SD, Gess M, et al., 2013, Central nervous system complications of hepatitis C virus infection, Viral Hepatitis, Editors: Thomas, Lok, Locarnini, Zuckerman, Oxford, Publisher: Wiley-Blackwell, ISBN: 9780470672952
The latest edition of Viral Hepatitis offers an essential resource of current information for hepatologists, gastroenterologists, infectious diseases specialists and other clinicians, researchers, public health physicians and National and ...
Hatzakis A, Van Damme P, Alcorn K, et al., 2013, The State of Hepatitis B and C in the Mediterranean and Balkan Countries: Report from a Summit Conference, JOURNAL OF VIRAL HEPATITIS, Vol: 20, Pages: 1-20, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 52
Sarri G, Westby M, Bermingham S, et al., 2013, GUIDELINES Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance, BMJ-BRITISH MEDICAL JOURNAL, Vol: 346, ISSN: 1756-1833
- Author Web Link
- Cite
- Citations: 49
Sheridan DA, Bridge SH, Crossey MME, et al., 2013, OMEGA-3 FATTY ACIDS AND/OR FLUVASTATIN IN HEPATITIS C PRIOR NON-RESPONDERS TO COMBINATION ANTI-VIRAL THERAPY - A PILOT RANDOMISED CLINICAL TRIAL, International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S372-S372, ISSN: 0168-8278
McPhail MJW, Leech R, Grover VPB, et al., 2013, Modulation of neural activation following treatment of hepatic encephalopathy, NEUROLOGY, Vol: 80, Pages: 1041-1047, ISSN: 0028-3878
- Author Web Link
- Cite
- Citations: 21
Khan SA, Davidson BR, Goldin RD, et al., 2012, Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update, GUT, Vol: 61, Pages: 1657-1669, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 570
Sheridan DA, Bridge SH, Felmlee DJ, et al., 2012, Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity, JOURNAL OF HEPATOLOGY, Vol: 57, Pages: 32-38, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 31
Cobbold JFL, Cox IJ, Brown AS, et al., 2012, Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C, Hepatology Research, Vol: 42, Pages: 714-720, ISSN: 1386-6346
Aim: Hepatic lipid is important in the pathogenesis and progression of hepatitis C-related liver disease. Polyunsaturated fatty acids have been shown to reduce viral replication in cell culture. Proton magic angle spinning magnetic resonance spectroscopy (1H MAS MRS) enables metabolic analysis of intact tissue. The aim was to examine the relationship between hepatic lipid composition by metabolic profiling of liver tissue at baseline and treatment response to pegylated-Interferon alfa2 and Ribavirin.Methods: Baseline liver biopsy samples from 31 patients with chronic hepatitis C were analyzed histologically and by 1H MAS MRS. Indices of lipid composition were derived and partial least squares discriminant analysis with cross-validation was used to predict treatment outcome.Results: Of 31 patients, 14 achieved sustained virological response (SVR). Lipid polyunsaturation (median (IQR)) was higher in SVR (3.41% (2.31)) than in treatment failure (TF) (2.15% (1.51)), P = 0.02. Lipid saturation was lower in SVR (85.9% (3.39)) than TF (86.7% (2.17)), P = 0.04. The total lipid content was lower in SVR (1.54% (0.81)) than TF (2.72% (3.47)), P = 0.004. Total choline to lipid ratio was higher in SVR (11.51% (9.99)) than TF (7.5% (6.82)), P = 0.007. Cross-validation correctly predicted the SVR group in 13 of 14 samples with 1 sample misclassified, and the TF group in all 17 samples.Conclusions: Lipid polyunsaturation was greater and total lipid lower in those with SVR, compared with TF. Metabolic profiling of intact liver biopsy samples predicted SVR with high accuracy. Hepatic lipid composition may impact on treatment success.
Cobbold JFL, Patel D, Fitzpatrick JA, et al., 2012, Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C, HEPATOLOGY RESEARCH, Vol: 42, Pages: 515-522, ISSN: 1386-6346
- Author Web Link
- Cite
- Citations: 10
Patel M, Shariff MIF, Ladep NG, et al., 2012, Hepatocellular carcinoma: diagnostics and screening, JOURNAL OF EVALUATION IN CLINICAL PRACTICE, Vol: 18, Pages: 335-342, ISSN: 1356-1294
- Author Web Link
- Cite
- Citations: 40
Khan SA, Emadossadaty S, Ladep NG, et al., 2012, Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?, JOURNAL OF HEPATOLOGY, Vol: 56, Pages: 848-854, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 213
McPhail MJ, Thomas HC, Taylor-Robinson HC, 2012, Magnetic Resonance Studies of the Brain in Liver Disease, Functional Molecular Imaging in Hepatology, Editors: Keiding, Sorensen, Bussum Netherlands, Publisher: Bentham Books, Pages: 160-182, ISBN: 978-1-60805-290-5
The diverse neurological manifestations of liver disease pose a diagnostic challenge for modern hepatologists with magnetic resonance (MR) techniques representing a highly profitable avenue to investigate structural and functional aspects of brain dysfunction. The commonest, but not sole neurological manifestation of liver disease, hepatic encephalopathy (HE), is a sequel of both acute and chronic liver failure, ranging from cognitive impairment only detectable on psychometric evaluation through to confusion, coma and death from cerebral edema. While there is widespread acceptance of its importance, there is little consensus on how best to diagnose and monitor HE. Clinical descriptions, psychometric testing, electroencephalography (EEG) and lately, imaging techniques, such as magnetic resonance (MR) imaging, MR spectroscopy and positron emission tomography (PET) have all have their proponents, but most putatively diagnostic paradigms remain the preserve of research establishments with an interest in HE. Of note, modern clinical MRI scanners with multinuclear MR spectroscopy capabilities and brain mapping software can objectively demonstrate structural and functional cellular changes (such as brain size and astrocyte swelling) using volumetric MRI, magnetization transfer MRI, diffusion-weighting MRI, functional MRI with oxygenation measurements and in vivo 1H and 31P MR spectroscopy, with the option of performing many sequences at a single sitting to maximize information gathering and cohort characterization. These techniques are also transferable to characterize non-HE cases of neurological dysfunction in liver disease, such as primary biliary cirrhosis, the neuropsychiatric sequela of non-cirrhotic chronic hepatitis C infection and metal deposition disorders, such as Wilson’s disease and hemochromatosis. This chapter describes the relative merits of these MR techniques and provides guidance on the directions for future research and translational into clinical
Grover VPB, Pavese N, Koh S-B, et al., 2012, Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation, JOURNAL OF VIRAL HEPATITIS, Vol: 19, Pages: E89-E96, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 98
Chambers JC, Zhang W, Sehmi J, et al., 2011, Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma, NATURE GENETICS, Vol: 43, Pages: 1131-1138, ISSN: 1061-4036
- Author Web Link
- Cite
- Citations: 409
Lim AKP, Patel N, Eckersley RJ, et al., 2011, A comparison of <SUP>31</SUP>P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease, JOURNAL OF VIRAL HEPATITIS, Vol: 18, Pages: E530-E534, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 10
Bridge S, Sheridan D, Felmlee D, et al., 2011, APOLIPOPROTEIN E AND LOW-DENSITY, APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN CHRONIC HEPATITIS C INFECTION: EVIDENCE FOR GENOTYPE-SPECIFIC MODULATION OF LIPID PATHWAYS, GUT, Vol: 60, Pages: A24-A24, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 1
Hatzakis A, Wait S, Bruix J, et al., 2011, The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference, JOURNAL OF VIRAL HEPATITIS, Vol: 18, Pages: 1-16, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 175
Sauvage VR, Levene AP, Nguyen HT, et al., 2011, Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease, LASERS IN SURGERY AND MEDICINE, Vol: 43, Pages: 392-400, ISSN: 0196-8092
- Author Web Link
- Open Access Link
- Cite
- Citations: 11
AbdAlla MSH, Taylor-Robinson SD, Sharif AW, et al., 2011, Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma, HPB, Vol: 13, Pages: 385-390, ISSN: 1365-182X
- Author Web Link
- Cite
- Citations: 24
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.